IPSEN (OTCMKTS:IPSEY – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $41.56 and traded as high as $48.76. IPSEN shares last traded at $48.76, with a volume of 109 shares.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Thursday. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.
View Our Latest Analysis on IPSEN
IPSEN Stock Performance
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Featured Stories
- Five stocks we like better than IPSEN
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
